PKM2 in carcinogenesis and oncotherapy.
Xia He1, Suya Du2, Tiantian Lei2
1Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China.
Oncotarget
|January 5, 2018
Summary
Pyruvate kinase M2 (PKM2) drives tumor growth by altering glucose metabolism. Targeting PKM2 offers a promising new strategy for cancer therapy and treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tumor cells exhibit high glucose uptake and aerobic glycolysis, a phenomenon known as the Warburg effect.
- Pyruvate kinase M2 (PKM2) is a key enzyme regulating glycolysis and is implicated in tumor progression.
- The Warburg effect, driven by PKM2, supports tumor growth, angiogenesis, metastasis, and apoptosis resistance.
Purpose of the Study:
- To elucidate the role of PKM2 in tumor cell development.
- To highlight PKM2 as a potential therapeutic target for cancer treatment.
- To summarize current research on PKM2-dependent glycometabolism and signaling pathways in tumors.
Main Methods:
- Literature review and synthesis of existing research on PKM2.
- Analysis of PKM2's function in glycolysis and the Warburg effect.
- Exploration of PKM2's involvement in tumor-related processes.
Main Results:
- PKM2 significantly influences glycolysis, contributing to the Warburg effect.
- PKM2 plays a critical role in tumor growth, angiogenesis, cell division, metastasis, and apoptosis.
- PKM2 has emerged as a viable target for novel oncotherapy strategies.
Conclusions:
- PKM2 is central to tumor cell metabolism and progression.
- Targeting PKM2 presents a promising avenue for developing new cancer treatments.
- Further research into PKM2-dependent pathways can inform future therapeutic interventions.
